Persephone Biosciences launches ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
Photo by Ishant Mishra
The company Persephone Biosciences is starting a new clinical trial of ARGONAUT: Stool and Blood Sample Bank for Cancer Patients.
ARGONAUT is a longitudinal, prospective, observational study that will enroll up to 4,000 advanced-stage cancer patients of diverse racial backgrounds to collect data used to develop precision microbiome medicines and for the identification of clinically actionable cancer-specific biomarkers to guide therapeutic decisions. Four types of solid tumor cancers will be profiled including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), colorectal cancer (CRC) and pancreatic cancer. Data collected from this study will be used to develop the most effective new therapies, via microbiome optimization, all to the benefit of patients and the physicians treating them. Stool and blood samples will be collected longitudinally and analyzed to determine the impact of gut microbiome composition and function on the immune system and efficacy of the treatment.
The patients who meet the entry criteria will provide 2 samples each of blood and stool over a 6-month period. Follow-up appointments will be held at 12, 18, and 24 months to collect tumor scan results and any other updated medical data, with no samples collected.
The clinical trial starts in December 2020 and will continue throughout December 2024.
The population that are excluded from participation: patients with known HIV, Hepatitis A, Hepatitis B, Hepatitis C, or SARS-CoV2; patients without the mental capacity to complete either a written or online questionnaire, alone or with assistance, or make sound decisions; women who are pregnant or who plan on becoming pregnant and women who are nursing.
The contacts and locations are the Persephone Biosciences, Inc, San Diego, California, United States, 92121.
For more details: https://ichgcp.net/clinical-trials-registry/NCT04638751
